VivoSeq
Other

Aggressive B-Cell NHL

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Aggressive B-cell NHL is an early-stage landscape with 0 programs across 2 companies. The most active players are Amgen, Shanghai Ming Ju Biotechnology Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalS

Shanghai Ming Ju Biotechnology Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00588094·20 enrolled
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Completed·Amgen logoAmgen·Phase 2/3·NCT02910063·41 enrolled
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Completed·UUniversity of Arizona·Phase 2·NCT01686165·5 enrolled
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
Active, not recruiting·SShanghai Ming Ju Biotechnology Co., Ltd.·Phase 2·NCT06093841·46 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)